219 related articles for article (PubMed ID: 37863057)
1. APOE4-promoted gliosis and degeneration in tauopathy are ameliorated by pharmacological inhibition of HMGB1 release.
Koutsodendris N; Blumenfeld J; Agrawal A; Traglia M; Yip O; Rao A; Kim MJ; Nelson MR; Wang YH; Grone B; Hao Y; Thomas R; Zilberter M; Yoon SY; Arriola P; Huang Y
Cell Rep; 2023 Oct; 42(10):113252. PubMed ID: 37863057
[TBL] [Abstract][Full Text] [Related]
2. Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits.
Koutsodendris N; Blumenfeld J; Agrawal A; Traglia M; Grone B; Zilberter M; Yip O; Rao A; Nelson MR; Hao Y; Thomas R; Yoon SY; Arriola P; Huang Y
Nat Aging; 2023 Mar; 3(3):275-296. PubMed ID: 37118426
[TBL] [Abstract][Full Text] [Related]
3. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist.
Litvinchuk A; Suh JH; Guo JL; Lin K; Davis SS; Bien-Ly N; Tycksen E; Tabor GT; Remolina Serrano J; Manis M; Bao X; Lee C; Bosch M; Perez EJ; Yuede CM; Cashikar AG; Ulrich JD; Di Paolo G; Holtzman DM
Neuron; 2024 Feb; 112(3):384-403.e8. PubMed ID: 37995685
[TBL] [Abstract][Full Text] [Related]
4. ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum.
Belinson H; Michaelson DM
J Neural Transm (Vienna); 2009 Nov; 116(11):1427-34. PubMed ID: 19370389
[TBL] [Abstract][Full Text] [Related]
5. Intracerebral Expression of AAV-APOE4 Is Not Sufficient to Alter Tau Burden in Two Distinct Models of Tauopathy.
Koller EJ; Gonzalez De La Cruz E; Weinrich M; Williams T; Cruz PE; Ryu D; Golde TE; Sullivan PM; Lewis J; Borchelt DR; Chakrabarty P
Mol Neurobiol; 2020 Apr; 57(4):1986-2001. PubMed ID: 31903524
[TBL] [Abstract][Full Text] [Related]
6. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy.
Shi Y; Yamada K; Liddelow SA; Smith ST; Zhao L; Luo W; Tsai RM; Spina S; Grinberg LT; Rojas JC; Gallardo G; Wang K; Roh J; Robinson G; Finn MB; Jiang H; Sullivan PM; Baufeld C; Wood MW; Sutphen C; McCue L; Xiong C; Del-Aguila JL; Morris JC; Cruchaga C; ; Fagan AM; Miller BL; Boxer AL; Seeley WW; Butovsky O; Barres BA; Paul SM; Holtzman DM
Nature; 2017 Sep; 549(7673):523-527. PubMed ID: 28959956
[TBL] [Abstract][Full Text] [Related]
7. Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation.
Saroja SR; Gorbachev K; Julia T; Goate AM; Pereira AC
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2108870119. PubMed ID: 35969759
[TBL] [Abstract][Full Text] [Related]
8. Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia.
Wang C; Xiong M; Gratuze M; Bao X; Shi Y; Andhey PS; Manis M; Schroeder C; Yin Z; Madore C; Butovsky O; Artyomov M; Ulrich JD; Holtzman DM
Neuron; 2021 May; 109(10):1657-1674.e7. PubMed ID: 33831349
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model.
Litvinchuk A; Huynh TV; Shi Y; Jackson RJ; Finn MB; Manis M; Francis CM; Tran AC; Sullivan PM; Ulrich JD; Hyman BT; Cole T; Holtzman DM
Ann Neurol; 2021 May; 89(5):952-966. PubMed ID: 33550655
[TBL] [Abstract][Full Text] [Related]
10. The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation.
Nelson MR; Liu P; Agrawal A; Yip O; Blumenfeld J; Traglia M; Kim MJ; Koutsodendris N; Rao A; Grone B; Hao Y; Yoon SY; Xu Q; De Leon S; Choenyi T; Thomas R; Lopera F; Quiroz YT; Arboleda-Velasquez JF; Reiman EM; Mahley RW; Huang Y
Nat Neurosci; 2023 Dec; 26(12):2104-2121. PubMed ID: 37957317
[TBL] [Abstract][Full Text] [Related]
11. Humanized APOE genotypes influence lifespan independently of tau aggregation in the P301S mouse model of tauopathy.
Williams T; Bathe T; Vo Q; Sacilotto P; McFarland K; Ruiz AJ; Hery GP; Sullivan P; Borchelt DR; Prokop S; Chakrabarty P
Acta Neuropathol Commun; 2023 Jun; 11(1):99. PubMed ID: 37337279
[TBL] [Abstract][Full Text] [Related]
12. ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice.
Liraz O; Boehm-Cagan A; Michaelson DM
Mol Neurodegener; 2013 May; 8():16. PubMed ID: 23684315
[TBL] [Abstract][Full Text] [Related]
13. Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer's disease and frontotemporal dementia.
Gaikwad S; Puangmalai N; Bittar A; Montalbano M; Garcia S; McAllen S; Bhatt N; Sonawane M; Sengupta U; Kayed R
Cell Rep; 2021 Jul; 36(3):109419. PubMed ID: 34289368
[TBL] [Abstract][Full Text] [Related]
14. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.
Brecht WJ; Harris FM; Chang S; Tesseur I; Yu GQ; Xu Q; Dee Fish J; Wyss-Coray T; Buttini M; Mucke L; Mahley RW; Huang Y
J Neurosci; 2004 Mar; 24(10):2527-34. PubMed ID: 15014128
[TBL] [Abstract][Full Text] [Related]
15. The Role of MAPK's Signaling in Mediating ApoE4-Driven Pathology In Vivo.
Salomon-Zimri S; Koren A; Angel A; Ben-Zur T; Offen D; Michaelson DM
Curr Alzheimer Res; 2019; 16(4):281-292. PubMed ID: 30819082
[TBL] [Abstract][Full Text] [Related]
16. Biologic TNF-α inhibitors reduce microgliosis, neuronal loss, and tau phosphorylation in a transgenic mouse model of tauopathy.
Ou W; Yang J; Simanauskaite J; Choi M; Castellanos DM; Chang R; Sun J; Jagadeesan N; Parfitt KD; Cribbs DH; Sumbria RK
J Neuroinflammation; 2021 Dec; 18(1):312. PubMed ID: 34972522
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice.
Liu M; Wang L; Gao J; Dong Q; Perry G; Ma X; Wang X
J Alzheimers Dis; 2019; 69(4):1077-1087. PubMed ID: 31156179
[TBL] [Abstract][Full Text] [Related]
18. Human apoE3 but not apoE4 rescues impaired astrocyte activation in apoE null mice.
Ophir G; Meilin S; Efrati M; Chapman J; Karussis D; Roses A; Michaelson DM
Neurobiol Dis; 2003 Feb; 12(1):56-64. PubMed ID: 12609489
[TBL] [Abstract][Full Text] [Related]
19. The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy.
Siman R; Cocca R; Dong Y
PLoS One; 2015; 10(11):e0142340. PubMed ID: 26540269
[TBL] [Abstract][Full Text] [Related]
20. Impact of APOE genotype on prion-type propagation of tauopathy.
Williams T; Ruiz AJ; Ruiz AM; Vo Q; Tsering W; Xu G; McFarland K; Giasson BI; Sullivan P; Borchelt DR; Chakrabarty P
Acta Neuropathol Commun; 2022 Apr; 10(1):57. PubMed ID: 35440098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
